# A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

> **NCT02068079** · PHASE1 · WITHDRAWN · sponsor: **Duke University**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vemurafenib and Trientine

## Key facts

- **NCT ID:** NCT02068079
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02068079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02068079, "A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02068079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*